Next Generation Pathogen Sequencing for Prediction of Infection in Rheumatic Disease

Infection Clinical Trial

Official title: Prediction of Infection in Patients With Rheumatic Disease at High Risk of Infection

Status Not yet recruiting

Clinical Trial Summary

The majority of patients diagnosed with rheumatic disease, such as systemic lupus erythematosus, inflammatory myositis, and vasculitis, will experience fever or infection during their course of therapy. The most common microbiologically documented infection is bacterial, virus, and fungal, which can be associated with the severity and mortality of disease. Current methods of diagnosis require a significant load of pathogen making early detection difficult. Delayed diagnosis and delayed optimal therapy of infection are associated with increased morbidity and mortality.

This study seeks to identify whether next generation sequencing (NGS) of pathogens can identify patients with infection treated with corticosteroid and immunosuppressive agents. This would enable preemptive targeted therapy to replace prophylaxis treatment which often leads to some adverse events and antibiotic resistance.

Clinical Trial Description

Plasma/Serum samples collected but not required for clinical care (discarded samples) will be collected and stored. Results of NGS will be compared between patients who develop definite infection immediately (within 72 hours) after sample collection, and those who remain well. Clinical data describing baseline information about the patient and rheumatic diseases, antibiotic and steroid or immunosuppressor therapy exposure, pathogen testing, immunology results, and infection-related events will be collected prospectively from the electronic medical record.

An initial exploratory phase will examine approximately 50 participants to determine whether the effectiveness of predicting infections. The study may then enroll up to 200 participants to collection additional data for analysis. ;

Related Conditions & MeSH terms

• Collagen Diseases
• Communicable Diseases
• Infection
• Rheumatic Diseases

• NCT number: NCT04226261
• Study type: Observational
• Source: Peking University People's Hospital
• Contact: Zhanguo Li, M.D, Ph.D
• Phone: +8601088324317
• Email: li99@bjmu.edu.cn
• Status: Not yet recruiting
• Start date: January 15, 2020
• Completion date: June 15, 2021